Abstract: The invention relates to the use of theobromine and/or its salts and/or its complexes optionally in admixture with other known active ingredients and inert solid or liquid carriers, additives and auxiliary agents for the manufacture of a pharmaceutical composition suitable for relieving cough syndrome. Further subject of the invention is a method of treatment of a human or animal subject being in condition where relieving of cough is desirable which comprise steps of administering in an effective amount theobromine and/or salts and/or its complexes optionally in admixture with other known active ingredients and suitable inert, solid or liquid carriers, additives and auxiliary agents.

Abstract: A process is described for the preparation of 4-Methyl-5-(2-Chloroalkyl)-thiazole wherein the alkyl ranges from C.sub.2 -C.sub.5, by providing the steps of either a) converting the 3-thiocyanato-5-chloro-2-alkanone into 2-chloro-4-methyl-5-(2-chloroalkyl)-thiazole by gaseous hydrochloric acid in an organic solvent and hydrogenating the compound in the presence of a metal catalyst in an organic solvent, or b) reacting 3-thiocyanato-5-choro-2-alkanone with aqueous mineral acid and treating the thiazole obtained with a halogenating agent, and hydrogenating the 2-chloro-4-methyl-5-(2-chloroalkyl)-thiazole in an organic solvent in presence of a metal catalyst.

Abstract: The present invention relates to a process for the preparation of compounds of general formula (I), wherein R stands for a straight chained C.sub.

Abstract: The invention relates to novel diphenylpropylamine derivatives of the general formula (I). ##STR1## R.sup.1 stands for hydrogen or a methyl group; R.sup.2 stands for hydrogen, a methyl or n-decyl group;Z means a phenyl group substituted by R.sup.3, R.sup.4 and R.sup.5, whereinR.sup.3 means hydrogen, fluorine, chlorine or bromine, or a nitro, C.sub.1-12 alkyl, C.sub.1-4 alkoxy, phenoxy or benzyloxy group;R.sup.4 and R.sup.5 represent hydrogen, chlorine or a hydroxy, alkoxy, benzyloxy, acetamino or carboxy group; orR.sup.4 and R.sup.5 together form a methylendioxy group;orZ may stand for a 4-methoxynaphtyl or 4-ethoxy-naphthyl group; andR.sup.6 stands for hydrogen or fluorine, with the proviso that each of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.6 cannot simultaneously stand for hydrogen, as well as their physiologically acceptable acid addition salts.The invention also relates to a process for the preparation of these compounds and to the pharmaceutical compositions containing these compounds.

Abstract: The present invention relates to new compounds of Formula I ##STR1## and physiologically acceptable salts thereof wherein A and B stand for oxygen or --CH.sub.2 group with the proviso that if A stands for oxygen, then B stands for --CH.sub.2 group and R stands for hydrogen and, if A represents a --CH.sub.2 group, then B stands for oxygen, R stands for a --CH.sub.2 Q group wherein Q stands for hydrogen, and pyrrolidino, piperidino or morpholino and a process for the preparation thereof and pharmaceutical compositions containing as active ingredient a compound of the Formula (I) or a physiologically acceptable salt thereof.

Abstract: Diuretic and saluretic tetrahydro-isoquinoline derivatives of the Formula (I) ##STR1## wherein R stands for hydrogen or chlorine,R.sup.1 and R.sup.2 are hydrogen, methoxy or ethoxy, andR.sup.3 and R.sup.4 are hydrogen or methyl,and a process for the preparation thereof as well as pharmaceutical compositions containing as active ingredients isoquinoline derivatives of the Formula (I). The compounds of Formula I are prepared by reacting a 2-amino-tetrahydro-isoquinoline derivative of the Formula (II) ##STR2## with a carboxylic acid derivative of the Formula (III) ##STR3## wherein x stands for chlorine, --OH, --OCH.sub.2 CN, --OCH.sub.3, --OC.sub.2 H.sub.5, --OCOOCH.sub.3 or --OCOOC.sub.2 H.sub.5R.sup.5 and R.sup.6 stand for hydrogen or together from CHN(CH.sub.3).sub.2 and in case of the Formula (Ia) ##STR4## splitting off the protective group in alkaline medium.

Abstract: The present invention relates to novel compounds of the general formula ##STR1## wherein R is hydrogen atom or a trifluoromethyl, carboxy, C.sub.2-5 alkoxycarbonyl, cyano, benzoyl, sulfamoyl or C.sub.1-4 alkylsulfonyl group;R.sup.1 is hydrogen atom or a linear or branched chain C.sub.1-4 alkyl, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfonyl, benzylthio, benzylsulfonyl, phenyl, hydroxy or mercapto group; andR.sup.2 is hydrogen or chlorine atom,as well as their pharmaceutically acceptable salts.The compounds according to the invention possess diuretic and saluretic activity with an advantageous Na/K ratio.

Abstract: The invention relates to new oxidiazole-alkyl-purine-derivatives of the Formula I ##STR1## and pharmaceutically acceptable salts thereof wherein A stands for C.sub.1-4 alkylene andR.sup.1 represents C.sub.1-6 alkyl, hydroxyalkyl, halogenoalkyl, carboxyalkyl, C.sub.5-6 cycloalkyl or aminoalkyl of the Formula --(CH.sub.2).sub.n --NR.sup.2 R.sup.3 in which group n is an integer 1-3; R.sup.2 and R.sup.3 each stand for hydrogen or C.sub.1-4 alkyl or together with the adjacent nitrogen atom they are attached to form a 5- or 6-membered nitrogen containing heterocyclic ring which may optionally comprise a further nitrogen atom or an oxygen atom as heteroatom; orR.sup.1 stands for phenyl, hydroxyphenyl, carboxyphenyl, benzyl or dimethoxybenzylThe compounds of the Formula I can be prepared by methods known per se and can be used in therapy as antitussive agents.

Abstract: The invention relates to a process for the preparation of compounds of formula (I) ##STR1## wherein R.sup.1 stands for hydrogen or the group COR.sup.2, whereinR.sup.2 stands for a straight or branched chained alkyl having 1 to 8 carbon atoms optionally substituted with phenyl, naphthyl, tetrahydronaphthyl or m-phenoxy-benzyl, cycloalkyl having 3 to 6 carbon atoms optionally substituted with one or more straight or branched chained alkyl or alkenyl having 1 to 6 carbon atoms, phenyl or naphthyl.The compounds of formula (I) are prepared according to the invention by(a) reacting esters of formula (II) ##STR2## wherein X stands for chlorine or bromine andR.sup.2 has the same meanings as defined above with a phenol alkali metal salt and(b) if desired converting the diphenyl ethers so obtained to a specific compound of formula (I), m-phenoxybenzyl alcohol by the hydrolysis of the ester group.

Abstract: 2,6-di-O-methyl-beta-cyclodextrin complexes of compounds of the formula (1a) ##STR1## wherein R.sup.2' stands for C.sub.1 to C.sub.12 alkyl or a group of the formula ##STR2## in which R.sup.11 is C.sub.1 to C.sub.4 alkyl;R.sup.12 is hydrogen or C.sub.1 to C.sub.4 alkyl;n is 0 or 1;p is 1 to 4;r is 1 to 4; andR.sup.3' and R.sup.4' are each C.sub.1 to C.sub.4 alkyl, or pharmaceutically salts thereof are disclosed, having analgesic activity.

Abstract: A process is disclosed for the preparation of a compound of the formula (XI) ##STR1## or a salt thereof, wherein R.sup.1 is hydrogen, halogen, C.sub.1 to C.sub.4 alkyl, C.sub.1 to C.sub.3 alkoxy, or trifluoromethyl;R.sup.5 is amino or C.sub.1 to C.sub.4 alkoxycarbonylamino; andR.sup.4" is C.sub.1 to C.sub.6 alkyl, C.sub.2 to C.sub.6 alkenyl, C.sub.2 to C.sub.6 alkynyl, cyclohexyl, benzyl, or 2-phenyl-ethyl, which comprises the steps of:(a) reacting a compound of the formula (VIII) ##STR2## or a salt thereof, with a basic nucleophilic compound to yield a salt of the formula (IX) ##STR3## wherein R.sup.4' is a lone pair of electrons, in which case an alkali metal or alkali earth metal cation forms a salt with the sulfur atom; and(b) reacting a salt of the formula (IX) with a compound of the formula (X)R.sup.4' --QwhereinQ is hydroxyl, halogen, 1/2SO.sub.4, 1/3PO.sub.3, SO.sub.3 C.sub.6 H.sub.5, or SO.sub.3 C.sub.6 H.sub.4 CH.sub.3 to yield the desired product.

Abstract: Antitussive compounds of the formula I ##STR1## or physiologically acceptable acid addition salts thereof are disclosed, where A stands for straight or branched chain C.sub.1-5 alkylene or ##STR2## R.sub.1 stands for straight or branched chain C.sub.1-10 alkyl, halogenoalkyl, hydroxyalkyl, C.sub.5-6 cycloalkyl, vinyl, 2-ethoxyethyl, carbonylalkyl or aminoalkyl of the formula ##STR3## wherein R stands for hydrogen or methyl, n is 0 to 3,R.sub.2 stands for hydrogen or straight or branched chain alkyl,R.sub.3 stands for hydrogen or straight or branched chain alkyl or,R.sub.2 and R.sub.3 together with the nitrogen atom may form a 5-6 membered ring, which ring can optionally contain an oxygen or a second nitrogen atom, the latter, optionally substituted by methyl or,R.sub.1 can stand for a phenyl group of the formulaR.sub.4 R.sub.5 C.sub.6 H.sub.3whereinR.sub.4 and R.sub.5 represent independently hydrogen, chlorine, hydroxy, methoxy, ethoxy, methyl or amino or,R.sub.

Abstract: An inclusion complex is disclosed of N-(1-phenylethyl)-3, 3-diphenyl-propylamine or its hydrochloride complexed with a cyclodextrin as well as a process for the preparation thereof and pharmaceutical compositions containing same. The new inclusion complexes have coronary dilatory activity and have greater water soluble than simple N-(1-phenylethyl)-3, 3-diphenyl-propyl amine or the hydrochloride thereof.

Abstract: A new process is disclosed for the preparation of a compound of the formula (VIII) ##STR1## wherein R.sup.1 is hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-3 alkoxy, or trifluoromethyl;R.sup.5 is amino or C.sub.1-4 alkoxycarbonylamino; or a salt thereof, which comprises reacting a compound of the formula (II) ##STR2## with gaseous chlorine and a rhodanide of the formula (III)R--SCN (III)wherein R represents a metal ion or ammonium.

Abstract: Arylacetic acid derivatives of the formula ##STR1## with R.sup.1, R.sup.2 and R.sup.3 specifically defined and which are useful as antirheumatic and antiinflammatory pharmaceuticals are prepared by catalytic hydrogenation of new compounds of the formula ##STR2## in which R and R.sup.10 are also specifically defined. The method of making the latter compound is also set forth.

Abstract: 2-(3-phenoxy-phenyl)-propionic acid or its pharmaceutical treatments, are prepared by hydrolyzing and partially decarboxylating ##STR1## wherein R=C.sub.1 -C.sub.6 alkyl or amino, the latter compounds being themselves new and, where R=C.sub.1 -C.sub.6 alkyl, have antiinflammatory pharmaceutical properties.

Abstract: The present invention relates to novel 7-substituted benzopyranes of formula (I), whereinR.sub.1 and R.sub.2 are hydrogen, alkyl of from 1 to 6 carbon atoms, hydroxyalkyl, alkenyl, cycloalkyl, phenylalkyl, dimethoxy-phenylalkyl, or R.sub.1 and R.sub.2 together with the joining nitrogen atom may represent a 5-7-membered heterocyclic ring,R.sub.3 is hydrogen, alkyl of from 1 to 4 carbon atoms or phenyl,R.sub.4 is hydrogen,R.sub.5 is hydrogen or phenyl, orR.sub.4 and R.sub.5 together may represent a bonding electron pair between the second and the third carbon atoms of the benzopyrane ring,R.sub.6 and R.sub.7 are hydrogen or they may represent an oxygen atom together,n is 1 or 2,with the proviso, that the pyrane ring may bear only one alkyl or phenyl substituent, and preparation process thereof.The novel compounds have valuable therapeutical effects, mainly in cardiotherapy.

Abstract: New compounds of the formula (VIIIa) are disclosed ##STR1## wherein R.sup.1 is hydrogen, methyl or ethyl;R.sup.2 is hydrogen, fluoro, or alkyl having 1 to 4 carbon atoms;R.sup.3 is hydrogen, phenyl, alkoxy having 1 to 6 carbon atoms; phenoxy, thenoyl, or benzoyl; orR.sup.2 and R.sup.3 together with the phenyl group to which they are attached form a naphthyl group which is unsubstituted or substituted by C.sub.1 to C.sub.4 alkyl or C.sub.1 to C.sub.4 alkoxy;R.sup.10 is phenylaminocarbonyl, 1-phenyl-5-tetrazolyl, a group --SO.sub.2 OMe, wherein Me is a metal atom selected from the group which consists of sodium or potassium, or a group --SO.sub.2 R.sup.6 in which R.sup.6 is alkyl having 1 to 4 carbon atoms, 4-methylphenyl, amino, C.sub.1 to C.sub.4 alkoxycarbonyl-amino, or benzoylamino, or R.sup.10 is a group ##STR2## in which R.sup.7 is cycloalkyl having 5 to 6 carbon atoms, and R is vinyl. The compounds are intermediates useful in the preparation of arylacetic acids having antiinflammatory compounds.

Abstract: Arylacetic acid derivatives of the formula ##STR1## with R.sup.1, R.sup.2 and R.sup.3 specifically defined and which are useful as antirheumatic and antiinflammatory pharmaceuticals are practiced by catalytic hydrogenation of new compounds of the formula ##STR2## in which R and R.sup.10 are also specifically defined. The method of making the latter compound is also set forth.

Abstract: 3-Phenoxybenzene derivatives are prepared by a method which comprises the steps of(a) chlorinating benzaldehyde with chlorine gas in the presence of a hydrocarbon and a Lewis acid catalyst to obtain 3-chlorobenzaldehyde; (b) reacting the 3-chlorobenzaldehyde with ethylene glycol to obtain 2-(3-chlorophenyl)-1,3-dioxolane; (c) etherifying said dioxolane with an alkali phenolate to yield the intermediate 2-(3-phenoxyphenyl)-1,3-dioxolane and converting this intermediate to the corresponding aldehyde, cyanohydrin, sulfonic acid salt or oxime derivative.